RecruitingPhase 3NCT06104566

Global Trial in APG2575 for Patients With CLL/SLL

A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (GLORA Study)

Sponsor

Ascentage Pharma Group Inc.

Enrollment

400 participants

Start Date

Dec 20, 2023

Study Type

INTERVENTIONAL

Conditions

CLL/SLL

Summary

This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This global trial is testing APG2575 (lisaftoclax), a targeted drug, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are already being treated with a BTK inhibitor (a common targeted therapy for this cancer type). The goal is to see if adding APG2575 to ongoing BTK inhibitor treatment improves outcomes. **You may be eligible if...** - You are 18 or older - You have a confirmed diagnosis of CLL or SLL - You have been on a BTK inhibitor (like ibrutinib or acalabrutinib) as your only treatment for at least 12 months - Your blood counts and organ function are within acceptable ranges - Your general health is adequate (ECOG 0–2) **You may NOT be eligible if...** - You are not responding well to your current BTK inhibitor treatment - Your blood counts are very low and not improving - You have severely reduced kidney or liver function Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGlisaftoclax +BTK inhibitor

lisaftolax + BTK inhibitor

DRUGBTK inhibitor

BTK inhibitor

Locations(135)

Ascentage Investigative Site

Tuscon, Arizona, United States

Ascentage Investigative Site

Anaheim, California, United States

Ascentage Investigative Site

Jacksonville, Florida, United States

Ascentage Investigative Site

Miami Beach, Florida, United States

Ascentage Investigative Site

Peoria, Illinois, United States

Ascentage Investigative Site

Boston, Massachusetts, United States

Ascentage Investigative Site

Ann Arbor, Michigan, United States

Ascentage Investigative Site

Greenville, North Carolina, United States

Ascentage Investigative Site

Houston, Texas, United States

Ascentage Investigative Site

Kingswood, Texas, United States

Ascentage Investigative Site

Richmond, Virginia, United States

Ascentage Investigative Site

Gosford, Australia

Ascentage Investigative Site

Perth, Australia

Ascentage Investigative Site

Westmead, Australia

Ascentage Investigative Site

Ghent, Belgium

Ascentage Investigative Site

La Louvière, Belgium

Ascentage Investigative Site

Leuven, Belgium

Ascentage Investigative Site

Ottignies, Belgium

Ascentage Investigative Site

Roeselare, Belgium

Ascentage Investigative Site

Sofia, Bulgaria

Ascentage Investigative Site

Sofia, Bulgaria

Ascentage Investigative Site

Sofia, Bulgaria

Ascentage Investigative Site

Sofia, Bulgaria

Ascentage Investigative Site

Halifax, Nova Scotia, Canada

Ascentage Investigative Site

Hefei, Anhui, China

Ascentage Investigative Site

Beijing, Beijing Municipality, China

Ascentage Investigative Site

Fuzhou, Fujian, China

Ascentage Investigative Site

Foshan, Guangdong, China

Ascentage Investigative Site

Guangzhou, Guangdong, China

Ascentage Investigative Site

Nanning, Guangxie, China

Ascentage Investigative Site

Zhengzhou, Henan, China

Ascentage Investigative Site

Wuhan, Hubei, China

Ascentage Investigative Site

Chenzhou, Hunan, China

Ascentage Investigative Site

Nanjing, Jiangsu, China

Ascentage Investigative Site

Suzhou, Jiangsu, China

Ascentage Investigative Site

Wuxi, Jiangsu, China

Ascentage Investigative Site

Nanchang, Jiangxi, China

Ascentage Investigative Site

Xi'an, Shaanxi, China

Ascentage Investigative Site

Binzhou, Shandong, China

Ascentage Investigative Site

Taiyuan, Shanxi, China

Ascentage Investigative Site

Luzhou, Sichuan, China

Ascentage Investigative Site

Yibin, Sichuan, China

Ascentage Investigative Site

Guangzhou, China

Ascentage Investigative Site

Hradec Králové, Czechia

Ascentage Investigative Site

Clermont-Ferrand, France

Ascentage Investigative Site

Le Mans, France

Ascentage Investigative Site

Lyon, France

Ascentage Investigative Site

Nantes, France

Ascentage Investigative Site

Nantes, France

Ascentage Investigative Site

Nîmes, France

Ascentage Investigative Site

Orléans, France

Ascentage Investigative Site

Poitiers, France

Ascentage Investigative Site

Pontoise, France

Ascentage Investigative Site

Strasbourg, France

Ascentage Investigative Site

Tours, France

Ascentage Investigative Site

Dresden, Germany

Ascentage Investigative Site

Dresden, Germany

Ascentage Investigative Site

München, Germany

Ascentage Investigative Site

Gandhinagar, Gujarat, India

Ascentage Investigative Site

Gurugramam, Haryana, India

Ascentage Investigative Site

Gurugramam, Haryana, India

Ascentage Investigative Site

Jhajjar, Haryana, India

Ascentage Investigative Site

Bangalore, Karnataka, India

Ascentage Investigative Site

Mysuru, Karnataka, India

Ascentage Investigative Site

Navi Mumbai, Maharashtra, India

Ascentage Investigative Site

Pune, Maharashtra, India

Ascentage Investigative Site

Delhi, National Capital Territory of Delhi, India

Ascentage Investigative Site

New Delhi, New Delhi, India

Ascentage Investigative Site

New Delhi, New Delhi, India

Ascentage Investigative Site

New Delhi, New Delhi, India

Ascentage Investigative Site

New Delhi, New, India

Ascentage Investigative Site

Madurai, Tamil Nadu, India

Ascentage Investigative Site

Hyderabad, Telangana, India

Ascentage Investigative Site

Kolkata, West Bengal, India

Ascentage Investigative Site

Kolkata, West Bengal, India

Ascentage Investigative Site

Puducherry, India

Ascentage Investigative Site

Haifa, Israel

Ascentage Investigative Site

Haifa, Israel

Ascentage Investigative Site

Jerusalem, Israel

Ascentage Investigative Site

Kfar Saba, Israel

Ascentage Investigative Site

Tel Aviv, Israel

Ascentage Investigative Site

Aviano, Italy

Ascentage Investigative Site

Brescia, Italy

Ascentage Investigative Site

Cona, Italy

Ascentage Investigative Site

Genova, Italy

Ascentage Investigative Site

Lecce, Italy

Ascentage Investigative Site

Meldola, Italy

Ascentage Investigative Site

Milan, Italy

Ascentage Investigative Site

Milan, Italy

Ascentage Investigative Site

Padova, Italy

Ascentage Investigative Site

Piacenza, Italy

Ascentage Investigative Site

Ravenna, Italy

Ascentage Investigative Site

Reggio Emilia, Italy

Ascentage Investigative Site

Rimini, Italy

Ascentage Investigative Site

Roma, Italy

Ascentage Investigative Site

Roma, Italy

Ascentage Investigative Site

Torino, Italy

Ascentage Investigative Site

Udine, Italy

Ascentage Investigative Site

Bydgoszcz, Poland

Ascentage Investigative Site

Krakow, Poland

Ascentage Investigative Site

Lodz, Poland

Ascentage Investigative Site

Skorzewo, Poland

Ascentage Investigative Site

Bucharest, Romania

Ascentage Investigative Site

Cluj-Napoca, Romania

Ascentage Investigative Site

Timișoara, Romania

Ascentage Investigative Site

Saint Petersburg, Kaluga Oblast, Russia

Ascentage Investigative Site

Kirov, Kirov Oblast, Russia

Ascentage Investigative Site

Kaluga, Russia

Ascentage Investigative Site

Kazan', Russia

Ascentage Investigative Site

Moscow, Russia

Ascentage Investigative Site

Moscow, Russia

Ascentage Investigative Site

Moscow, Russia

Ascentage Investigative Site

Petrozavodsk, Russia

Ascentage Investigative Site

Saint Petersburg, Russia

Ascentage Investigative Site

Saint Petersburg, Russia

Ascentage Investigative Site

Sochi, Russia

Ascentage Investigative Site

Syktyvkar, Russia

Ascentage Investigative Site

Bratislava, Slovakia

Ascentage Investigative Site

Martin, Slovakia

Ascentage Investigative Site

Barcelona, Spain

Ascentage Investigative Site

Barcelona, Spain

Ascentage Investigative Site

Palma de Mallorca, Spain

Ascentage Investigative Site

Santander, Spain

Ascentage Investigative Site

Valencia, Spain

Ascentage Investigative Site

Kepez, Turkey (Türkiye)

Ascentage Investigative Site

Trabzon, Turkey (Türkiye)

Ascentage Investigative Site

Birmingham, United Kingdom

Ascentage Investigative Site

Bournemouth, United Kingdom

Ascentage Investigative Site

Liverpool, United Kingdom

Ascentage Investigative Site

London, United Kingdom

Ascentage Investigative Site

Manchester, United Kingdom

Ascentage Investigative Site

Stoke-on-Trent, United Kingdom

Ascentage Investigative Site

Swansea, United Kingdom

Ascentage Investigative Site

West Bromwich, United Kingdom

Ascentage Investigative Site

Wolverhampton, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06104566

Related Trials

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

NCT073424785 locations

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

NCT067088975 locations

A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

NCT0631945610 locations

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

NCT047757454 locations

REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)

NCT0452342818 locations